The United States hepatitis vaccines market is projected to boost over the forecast period of 2021 to 2027.
This new market report provides a comprehensive analysis of the fast-evolving, high-growth U.S hepatitis vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the U.S. hepatitis vaccines market. The report provides historical market data for 2015 – 2020, and forecasts from 2021 till 2027.
The report additionally provides a detailed evaluation of the leading 6 key marketed hepatitis vaccines market assessments, data from 2015 to 2020, and forecasts to 2027. Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States hepatitis vaccines market.
An all-inclusive examination has been done on the pricing trends and analysis of the hepatitis vaccines in the United States. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report concludes with the profiles of the key players in the U.S. hepatitis vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, and recent development.
Other emerging players are making novel era-based vaccines that are in all possible to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.
The Following 6 Leading Vaccines of the U.S. Hepatitis Vaccines Market are Detailed with Market Size and Six-Year Forecast:
• Havrix
• Twinrix
• Engerix-B
• Vaqta
• Heplisav-B
• Recombivax HB
This Comprehensive U.S Hepatitis Vaccines Report Provides:
• The Market Size of the United States Hepatitis Vaccines Market with Six Years Forecast
• The Market Size of the 6 Leading Hepatitis Vaccines with Six Years Forecast
• Delivers Inclusive Insights on the Latest Pricing Trends and Analysis
• Detailed Insights into the Regulatory Framework of the United States Hepatitis Vaccines Market
• Features Reimbursement Patterns of the United States Hepatitis Vaccines Market
• Analyses the Most Recent Clinical Trials of the Hepatitis Vaccines between 2019 and 2020
• Delivers an In-Depth Analysis of Evolving Market Trends, Drivers and Restraints of the United States Hepatitis Vaccines Market
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Business Overview, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The Key and Emerging Market Players for the U.S Hepatitis Vaccines Market are Listed Below:
• GeoVax, Inc.
• Merck
• Cytuvax
• Vaccitech
• VBI Vaccines, Inc.
• GeneOne Life Science , Inc.
• GlaxoSmithKline (GSK)
• Dynavax Technologies
Key Questions Answered in this Report:
• What is the current scenario of the U.S. hepatitis vaccines market?
• What is the total market size and forecast (until 2027) for the U.S. hepatitis vaccines market?
• What are the key marketed hepatitis vaccines available in the United States?
• What are the major drivers of the United States hepatitis vaccines market?
• What are the major inhibitors of the United States hepatitis vaccines market?
• What is the reimbursement pattern in the United States hepatitis vaccines market?
• What is the regulatory framework in the United States hepatitis vaccines market?
• What are the upcoming hepatitis vaccines that will have a significant impact on the market in the future?
• Who are the top market players? What are their happenings, current developments, and scenarios?
• Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
• How is the market predicted to develop in the future?
'
1. Executive Summary
2. United States Hepatitis Vaccines Market Size and Forecast (2015 – 2027)
3. Key Marketed Hepatitis Vaccines Market Value in the United States (2015 – 2027)
3.1 Havrix/Twinrix/Engerix-B
3.2 Vaqta
3.3 Recombivax HB
3.4 Heplisav-B
4. Key Drivers and Inhibitors of the United States Hepatitis Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors
5. United States Hepatitis Vaccines Pricing Trends and Analysis
6. Reimbursement Environment of the United States Hepatitis Vaccines Market
7. Regulatory Framework of the United States Hepatitis Vaccines Market
8. Hepatitis Vaccines Clinical Trials Insight by Phase, Company, and Country
9. Key Companies Profiles (Business Overview, Key Marketed Hepatitis Vaccines, and Recent Development)
9.1 Merck
9.2 GlaxoSmithKline (GSK)
9.3 Dynavax Technologies
10. Emerging Player Profiles (Business Overview, Promising Vaccines in the Clinical Development, and Recent Development)
10.1 Vaccitech
10.2 VBI Vaccines
10.3 GeoVax
10.4 GeneOne Life Science
10.5 Cytuvax
List of Tables:
Table 6-1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 10-1: Vaccitech Promising Hepatitis Vaccines in the Clinical Development
Table 10-2: VBI Vaccines Hepatitis Promising Vaccines in the Clinical Development
Table 10-3: GeoVax Promising Hepatitis Vaccines in the Clinical Development
Table 10-4: GeneOne Life Science Promising Hepatitis Vaccines in the Clinical Development
Table 10-5: Cytuvax Promising Hepatitis Vaccines in the Clinical Development
List of Figures:
Figure 2-1: United States Hepatitis Vaccines Market Size (Million US$), 2015 – 2020
Figure 2-2: United States Hepatitis Vaccines Market Size Forecast (Million US$), 2021 – 2027
Figure 3-1: United States Havrix/Twinrix/Engerix-B Market Value (Million US$), 2015 – 2020
Figure 3-2: United States Havrix/Twinrix/Engerix-B Market Value Forecast (Million US$), 2021 – 2027
Figure 3-3: United States Vaqta Market Value (Million US$), 2015 – 2020
Figure 3-4: United States Vaqta Market Value Forecast (Million US$), 2021 – 2027
Figure 3-5: United States Recombivax HB Market Value (Million US$), 2015 – 2020
Figure 3-6: United States Recombivax HB Market Value Forecast (Million US$), 2021 – 2027
Figure 3-7: United States Heplisav-B Market Value (Million US$), 2015 – 2020
Figure 3-8: United States Heplisav-B Market Value Forecast (Million US$), 2021 – 2027
